| 30/09/26 | 13:00:00 | 30 Sept 2026 | | Interim Results for the Six Months to June 30, 2026, and Business Update | GNW |
| 25/09/26 | 07:00:00 | 25 Sept 2026 | | The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer | GNW |
| 16/09/26 | 16:00:00 | 16 Sept 2026 | | Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial | GNW |
| 14/09/26 | 07:00:00 | 14 Sept 2026 | | Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee | GNW |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors | GNW |
| 01/06/26 | 07:00:00 | 1 Jun 2026 | | Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 | GNW |
| 19/05/26 | 07:14:00 | 19 May 2026 | | Unaudited Preliminary Results for the Year Ended December 31, 2025 | GNW |
| 06/05/26 | 07:00:00 | 6 May 2026 | | Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 | GNW |
| 21/04/26 | 17:00:00 | 21 Apr 2026 | | Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform | GNW |
| 16/10/17 | 11:42:30 | 16 Oct 2017 | | Hardman Res.: R&D accelerated to advance assets | RNS |
| 12/10/17 | 08:00:03 | 12 Oct 2017 | | Avacta to Present at Shares Spotlight Evening | RNS |
| 10/10/17 | 08:00:05 | 10 Oct 2017 | | Avacta to Present at Major US Conference | RNS |
| 09/10/17 | 17:02:09 | 9 Oct 2017 | | Director Dealing and Issue of Equity | RNS |
| 05/10/17 | 08:00:02 | 5 Oct 2017 | | Research collaboration with FIT Biotech Oy | RNS |
| 04/10/17 | 08:00:04 | 4 Oct 2017 | | Preliminary Results | RNS |
| 02/10/17 | 08:00:05 | 2 Oct 2017 | | Avacta establishes US business development team | RNS |
| 07/09/17 | 08:00:07 | 7 Sept 2017 | | Notice of Results | RNS |
| 21/08/17 | 13:00:28 | 21 Aug 2017 | | Director/PDMR Shareholding | RNS |
| 07/08/17 | 08:00:04 | 7 Aug 2017 | | Trading Update | RNS |
| 28/07/17 | 14:15:28 | 28 Jul 2017 | | Director/PDMR Shareholding | RNS |
| 05/07/17 | 08:00:05 | 5 Jul 2017 | | Director Dealing and Issue of Equity | RNS |
| 04/07/17 | 08:00:04 | 4 Jul 2017 | | Manchester ShareSoc Growth Company Seminar | RNS |
| 05/06/17 | 08:00:04 | 5 Jun 2017 | | ShareSoc Growth Company Seminar | RNS |
| 22/05/17 | 08:00:10 | 22 May 2017 | | 2 Biotech's Licence Affimers for Research Use | RNS |
| 10/05/17 | 08:00:07 | 10 May 2017 | | Key Affimer Patent To Be Granted in China | RNS |
| 08/05/17 | 14:21:20 | 8 May 2017 | | Hardman Research: De-risking Moderna's partnership | RNS |
| 05/05/17 | 08:00:09 | 5 May 2017 | | Presenting at the Hardman Private Investor Forum | RNS |
| 02/05/17 | 08:00:20 | 2 May 2017 | | Avacta to Present at BioTrinity 2017 | RNS |
| 24/04/17 | 08:00:07 | 24 Apr 2017 | | Diagnostics firm take rights to several Affimers | RNS |
| 19/04/17 | 08:00:10 | 19 Apr 2017 | | Avacta to Present at the Shares Spotlight Evening | RNS |
| 12/04/17 | 08:15:03 | 12 Apr 2017 | | Hardman Research: Another important box ticked | RNS |
| 06/04/17 | 15:23:01 | 6 Apr 2017 | | Holding(s) in Company | RNS |
| 06/04/17 | 15:23:01 | 6 Apr 2017 | | Holding(s) in Company | RNS |
| 06/04/17 | 11:22:50 | 6 Apr 2017 | | Director/PDMR Shareholding | RNS |
| 03/04/17 | 08:00:10 | 3 Apr 2017 | | Interim Results for the Period Ended 31 Jan 2017 | RNS |
| 03/04/17 | 08:00:10 | 3 Apr 2017 | | Results of Immunogenicity Study with Human Samples | RNS |
| 31/03/17 | 10:31:14 | 31 Mar 2017 | | Avacta Presents at Investor Evening Hosted by TPI | RNS |
| 31/03/17 | 08:00:15 | 31 Mar 2017 | | London Growth and Innovation Forum Presentation | RNS |
| 22/03/17 | 09:00:16 | 22 Mar 2017 | | Avacta to present at the UK Investor Show | RNS |
| 21/03/17 | 07:15:01 | 21 Mar 2017 | | Hardman Research: Low response would be positive! | RNS |
| 16/12/16 | 17:14:14 | 16 Dec 2016 | | Holding(s) in Company | RNS |
| 01/12/16 | 07:00:04 | 1 Dec 2016 | | Notice of AGM, Accounts and Directorate Change | RNS |
| 02/11/16 | 07:00:07 | 2 Nov 2016 | | CAR-T Cell Therapy Research Collaboration in US | RNS |
| 21/10/16 | 12:39:09 | 21 Oct 2016 | | Director's Dealing | RNS |
| 17/10/16 | 08:00:07 | 17 Oct 2016 | | Prelim Results for the Year Ended 31 July 2016 | RNS |
| 04/10/16 | 16:28:27 | 4 Oct 2016 | | Issue of Equity | RNS |
| 26/09/16 | 12:21:10 | 26 Sept 2016 | | Notice of Results | RNS |
| 22/09/16 | 08:00:12 | 22 Sept 2016 | | Positive results from first preclinical studies | RNS |
| 12/09/16 | 08:00:12 | 12 Sept 2016 | | Change of Adviser | RNS |
| 31/08/16 | 15:17:33 | 31 Aug 2016 | | Change of Registered Office | RNS |
